Shortened time interval between colorectal cancer diagnosis and risk testing for hereditary colorectal cancer is not related to higher psychological distress

Por Landsbergen, K. M., Prins, J. B., Brunner, H. G., Hoogerbrugge, N.
Publicado em 2010

Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI

Por Veltman, J., Mann, R., Kok, T., Obdeijn, I. M., Hoogerbrugge, N., Blickman, J. G., Boetes, C.
Publicado em 2008

Surveillance of women at high risk for hereditary ovarian cancer is inefficient

Por Oei, A L, Massuger, L F, Bulten, J, Ligtenberg, M J, Hoogerbrugge, N, de Hullu, J A
Publicado em 2006

Lifestyle Risk Factors for Breast Cancer in BRCA1/2-Mutation Carriers Around Childbearing Age

Por van Erkelens, A., Derks, L., Sie, A. S., Egbers, L., Woldringh, G., Prins, J. B., Manders, P., Hoogerbrugge, N.
Publicado no J Genet Couns (2016)

Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of ‘easy to apply’ probability models

Por Bodmer, D, Ligtenberg, M J L, van der Hout, A H, Gloudemans, S, Ansink, K, Oosterwijk, J C, Hoogerbrugge, N
Publicado em 2006

Childhood neuroendocrine tumours: a descriptive study revealing clues for genetic predisposition

Por Diets, I J, Nagtegaal, I D, Loeffen, J, de Blaauw, I, Waanders, E, Hoogerbrugge, N, Jongmans, M C J
Publicado no Br J Cancer (2017)

The genetic heterogeneity of colorectal cancer predisposition - guidelines for gene discovery

Por Hahn, M. M., de Voer, R. M., Hoogerbrugge, N., Ligtenberg, M. J. L., Kuiper, R. P., van Kessel, A. Geurts
Publicado no Cell Oncol (Dordr) (2016)

Reply: Familial ovarian screening: how to address abnormal TVU findings and its influence on the efficacy of screening?

Por Oei, A L M, Massuger, L F A G, Bulten, J, Ligtenberg, M J L, Hoogerbrugge, N, de Hullu, J A
Publicado em 2006

Electronic reminders for pathologists promote recognition of patients at risk for Lynch syndrome: cluster-randomised controlled trial

Por Overbeek, L. I., Hermens, R. P., van Krieken, J. H., Adang, E. M., Casparie, M., Nagengast, F. M., Ligtenberg, M. J., Hoogerbrugge, N.
Publicado em 2010

Psychological distress in newly diagnosed colorectal cancer patients following microsatellite instability testing for Lynch syndrome on the pathologist’s initiative

Por Landsbergen, K. M., Prins, J. B., Brunner, H. G., van Duijvendijk, P., Nagengast, F. M., van Krieken, J. H., Ligtenberg, M., Hoogerbrugge, N.
Publicado em 2012

Very low prevalence of germline MSH6 mutations in hereditary non-polyposis colorectal cancer suspected patients with colorectal cancer without microsatellite instability

Por Kets, C M, van Krieken, J H J M, Hebeda, K M, Wezenberg, S J, Goossens, M, Brunner, H G, Ligtenberg, M J L, Hoogerbrugge, N
Publicado em 2006

Deficient mismatch repair system in patients with sporadic advanced colorectal cancer

Por Koopman, M, Kortman, G A M, Mekenkamp, L, Ligtenberg, M J L, Hoogerbrugge, N, Antonini, N F, Punt, C J A, van Krieken, J H J M
Publicado em 2009

Genome-wide scanning for linkage in 56 Dutch breast cancer families selected for a minimal probability of being due to BRCA1 or BRCA2

Por Oldenburg, RA, Kroeze-Jansema, K, Houwing, JJ, Kraan, J, Klijn, JG, Hoogerbrugge, N, Ligtenberg, MJ, van Asperen, CJ, Vasen, HF, Meijers-Heijboer, H, Cornelisse, CJ, Devilee, P
Publicado no Breast Cancer Res (2005)

Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation

Por van Roosmalen, M S, Stalmeier, P F M, Verhoef, L C G, Hoekstra-Weebers, J E H M, Oosterwijk, J C, Hoogerbrugge, N, Moog, U, van Daal, W A J
Publicado em 2004

Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers

Por van der Post, R S, Kiemeney, L A, Ligtenberg, M J L, Witjes, J A, Hulsbergen-van de Kaa, C A, Bodmer, D, Schaap, L, Kets, C M, van Krieken, J H J M, Hoogerbrugge, N
Publicado em 2010

Cancer risks in BRCA2 families: estimates for sites other than breast and ovary

Por van Asperen, C J, Brohet, R, Meijers-Heijboer, E, Hoogerbrugge, N, Verhoef, S, Vasen, H, Ausems, M, Menko, F, Gomez, G, Klijn, J, Hogervorst, F, van Houwelingen, J C, van't, V, Rookus, M, van Leeuwen, F E, on, b
Publicado em 2005

Patients with an unexplained microsatellite instable tumour have a low risk of familial cancer

Por Overbeek, L I H, Kets, C M, Hebeda, K M, Bodmer, D, der Looij, E van, Willems, R, Goossens, M, Arts, N, Brunner, H G, van Krieken, J H J M, Hoogerbrugge, N, Ligtenberg, M J L
Publicado em 2007

Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations

Por Leegte, B, van der Hout, A H, Deffenbaugh, A, Bakker, M, Mulder, I, ten, B, Leenders, E, Wesseling, J, de Hullu, J, Hoogerbrugge, N, Ligtenberg, M, Ardern-Jones, A, Bancroft, E, Salmon, A, Barwell, J, Eeles, R, Oosterwijk, J
Publicado em 2005

Cost effectiveness of a new strategy to identify HNPCC patients

Por Kievit, W, de Bruin, J H F M, Adang, E M M, Severens, J L, Kleibeuker, J H, Sijmons, R H, Ruers, T J, Nagengast, F M, Vasen, H F A, van Krieken, J H J M, Ligtenberg, M J L, Hoogerbrugge, N
Publicado em 2005

Colorectal cancer risk variants at 8q23.3 and 11q23.1 are associated with disease phenotype in APC mutation carriers

Por Ghorbanoghli, Z., Nieuwenhuis, M. H., Houwing-Duistermaat, J. J., Jagmohan-Changur, S., Hes, F. J., Tops, C. M., Wagner, A., Aalfs, C. M., Verhoef, S., Gómez García, E. B., Sijmons, R. H., Menko, F. H., Letteboer, T. G., Hoogerbrugge, N., van Wezel, T., Vasen, H. F. A., Wijnen, J. T.
Publicado no Fam Cancer (2016)